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& Abstract: In recent decades, there has been a revision of
the role of institutional review boards with the intention of
protecting human subjects from harm and exploitation in
research. Informed consent aims to protect the subject by
explaining all of the benefits and risks associated with a
specific research project. To date, there has not been a review
published analyzing issues of informed consent in research in
the field of genetic/Omics in subjects with chronic pain, and
the current review aims to fill that gap in the ethical aspects of
such investigation. Despite the extensive discussion on ethical
challenges unique to the field of genetic/Omics, this is the first
attempt at addressing ethical challenges regarding Informed
Consent Forms for pain research as the primary focus. We see
this contribution as an important one, for while ethical issues
are too often ignored in pain research in general, the
numerous arising ethical issues that are unique to pain
genetic/Omics suggest that researchers in the field need to
pay even greater attention to the rights of subjects/patients.
This article presents the work of the Ethic Committee of the
Pain-Omics Group (www.painomics.eu), a consortium of 11
centers that is running the Pain-Omics project funded by the
European Community in the 7th Framework Program theme
(HEALTH.2013.2.2.1-5—Understanding and controlling pain).
The Ethic Committee is composed of 1 member of each group
of the consortium as well as key opinion leaders in the field of
ethics and pain more generally. &
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THE NEED FOR INFORMED CONSENT
The primary purpose of informed consent is to provide
potential subjects with the occasion to make unbiased
decisions based on the questions raised by the subject as
well as the information provided by the study personnel
on whether or not to take part (or to continue to
participate) in a clinical research study. Every informed
consent can only be valid when 2 key conditions are
satisfied: (1) the information provided to the subject and
(2) the consent of the subject.1 There is a robust body of
literature specifying the limitations of informed consent
to obtain these targets.2–6 A vital point is the question of
how much information is essential for the patient to be
considered “informed” and whether this information
can affect the results of the study, especially in patients
with chronic pain for whom a placebo effect could be of
great importance. Baroness O’Neill alleged that differ-
ent rituals or procedures of consent should be used
according to the level of risk.7 Therefore, one may argue
that provisional language contained within the Omics
research protocol is robust enough to meet or exceed the
definition of “minimal risk” and may seek a waiver of
consent from the appropriate institutional review board
(IRB). A risk can be considered minimal when it puts
subjects at levels of risk no greater than those experi-
enced in everyday life. In this context, the risks of Omics
may be low (a simple sample of human biological
materials [HBMs]) or high (associated genetics maps of
society and unpredictable scenarios). The risk for
identification becomes progressively greater as subjects
provide data via the Internet, such as names, addresses,
and genetic information voluntarily and independent of
research.8 Furthermore, not all subjects want to be
informed of all of the details of specific risks, while
others require a deeper understanding.9 Going into
greater depth, what is the meaning of “understanding”?
We agree with the opinion of Kettle that both clinical
experience and empirical data confirm that patients’
understanding of data regarding “diagnoses, proce-
dures, risks, and prognoses” diverge widely.10
INFORMED CONSENT AND BIOBANKING
There is a need for a clear definition of what constitutes
essential information as a part of informed consent in a
research study where tissue samples and genetic
materials can be stored and used at later dates, such as
in Omics research. It is important to emphasize the
confidentiality of all information (and how it will be
addressed) as an aspect of genuine informed consent.
Furthermore, the commercialization possibilities of the
results, how participation in such research studies can
affect a subject’s ability to be insured, and whether or
not the outcomes of the research studies will be made
available to the research subject are questions to which
research subjects may desire answers.11,12 However, are
those necessary concepts sufficient when we consider the
vast information content involved in biobanking? Cur-
rently, large repositories of HBMs are being generated
by both private and public sectors as by-products of
ongoing research and for a wide variety of research uses
in the future. Furthermore, those HBMs can reveal, in
varying degrees, a wealth of information, such as
information about the health status of the subject at
the time of collection, as well as unique heritable
identifiers that could lead to identification of specific
individual subjects. There is a possibility that these
developments could erode the effectiveness of individual
or societal protections.13 Furthermore, these points may
represent legal and ethical obstacles with the advances in
global network of data sharing and use of health records
for further research studies that are related to the
original study, and not delineated in the original
informed consent. The principal challenge is that no
one can anticipate the type of information or data to be
extracted from stored samples, such as biobank data in
the future, or predict who or what entity can or will have
access to them.14 This scenario advises for two possible
options. The first option is to adapt a language that will
be broad enough to cover such scenarios. The second
option is to have multiple updates to the original consent
form to be obtained from the subjects over time.
However, both options have their drawbacks. The first
option of adapting a broader language to anticipate and
cover for any and all future use of the biobank data is
viewed as too vague to be considered,15 although it may
be considered a good compromise when managed
adequately.16 The second option of continuous updates
over the life of the samples in the biobank represents
challenges from both practical and logistical points of
view and creates a disincentive for biobank research.17
There are several ethical concerns regarding informed
consent and biobanking that have been elucidated in the
literature.13,18–20 Globally, biobanks are being set up in
countries such as Canada (www.cartagene.qc.ca),
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Iceland (www.decode.com), the United Kingdom
(www. ukbiobank.ac.uk), and Germany (http://na-
tional-kohorte.de), and there are more countries who
are in the process of developing similar repositories for
biological samples. The biological samples stored in
such biobanks are often combined with other pertinent
medical or protected health information (PHI) of the
individuals.21 These biobanks are seen as an auspicious
method for providing insights into the associations
between environmental factors and genetics and fur-
thering our understanding of the causes of common
diseases, thereby contributing to the development of the
innovation in treatments and contributing to the devel-
opment of preventative measures.14 The considerable
optimism surrounding potential benefits to be gained
from the research and the knowledge to be gained from
the research using samples from biobanks highlights the
seriousness of striking a balance between the individual
concerns and the interest of society as a whole. On the
other hand, there is concern that the use of biobanking
may compromise privacy and confidentiality. Therefore,
one significant question is how to move from a “one
study/one informed consent” paradigm to something
more appropriate for the extensive potential impact of
biobanking on society.13,16,21,22 Individual consent
clearly needs to be revised to take societal level interests
into consideration.
STANDARDIZATION OF INFORMED CONSENT
In the field of chronic pain, biobanks could be quite useful
in improving the quality and availability of large popu-
lations for studying pain syndromes, for which large
population enrollment is often challenging. An addi-
tional topic of great importance is how to characterize the
phenotype of pain and how to describe it to the subject in
the provision of informed consent. In most genetic/Omic
trials, it is not sufficient23,24 to consider efficacy based
merely on “a number” as assessed by a numeric rating
scale or visual analog scale. Rather, it is crucial to more
broadly capture the outcome experience of subjects with
chronic pain25 by assessing other outcome dimensions
(eg, emotional status, functionality). Furthermore, we
should strive for a general international consensus
regarding the phenotype measures of chronic pain that
would be relevant to correlate with genetic/Omic data.
Such a widespread consensus would serve to improve the
results of genetic/Omic studies of pain and additionally
willmake the process of informed consentmore objective
and standardized. For example, the Pain-Omics group
has adopted a minimal common dataset of clinical
features on all of its genetic/Omic studies that clarifies
informed consent for subjects.
Another salient concern is related to the use of
anonymous data. In the past decades, the concept that
the use of coded information could not result in any harm
to the individual was frankly inaccurate.8 According to
this notion, no informed consent is needed if the
biological samples used for research do not contain any
personal identifiers to prevent identification of the subject
who provided them.26 In fact, there are greater than 307
million human biological materials being stored in the
United States, and most of them were obtained without
informed consent for research.27 Some countries accept
the waived consent for some research. Examples of such
are Canada, based upon its Personal Information Pro-
tection and Electronic Documents Act (PIPEDA),28 or
the United States according to the federal regulations
under 45CFR46.116, known as common rules summary
conditions under which data may be used for research
purposes without individual consent.29 In other coun-
tries, it is almost impossible to use data and samples taken
withoutwritten consent for research purposes outside the
institution in which they were taken. For example, in
Germany, the Federal Data Protection Act prohibits use
of data (and thus data generated from biomaterial)
without permission of the donor or a legal representative.
Furthermore, recent studies have demonstrated the
ease of deducing specific identity from different public
datasets. For example, in one study,8 the researchers
were able to find the identity of nearly 50 participants
through publically available information. Such results
point to the fact of how easily data are accessible in the
networks. Therefore, specific consideration should be
paid to protect and preserve the privacy rights of
research participants in this new era of information
technology.30 The suggestion of the authors is to limit
access to the minimum staff necessary to perform the
primary study, ensuring appropriate dissemination of
the results. The use of anonymous/pseudonymous data
is mandatory. Research institutions in some nations
attempt to reduce the impact of this problem by
informing the subject about the possibility of public
identification when genetic information is online.
OPTIONS FOR INFORMED CONSENT
An additional question relates to researchers’ options
regarding identifiable samples with associated relevant
clinical information. There are multiple options:
Challenges in Genetic Research  3
contacting sample providers and attempting to obtain
informed consent (which is likely to be challenging
logistically), making samples unidentifiable (thereby
limiting the empirical value of the samples through
deletion of the connection to the highly relevant clinical
information), or seeking a waiver of consent from the
IRB (minimal risk standard) if permissible. In contrast to
prospective research, informed consent for Omics is no
different from that pertaining to clinical trials. However,
there is substantial divergence from traditional research,
which pertains to the possibilities that the collection of
HBMs will be stored for future undetermined use and
that samples and data will be handed over to other
institutions.
Thus, we suggest that informed consent forms of
prospective studies consider including the following
options26:
 Refusing to use the HBMs for any research.
 If subject agrees to the use of HBM consider the
following options
○ HBM use without PHI
 Permitting only unidentified or unlinked use.
 Permitting coded use for any type of future
research.
○ HBM use with PHI (all or parts of it) permitted
 Permitting coded or identified use for a
particular study, with no further contact
with the subject regardless of health or
genetic discovery.
 Permitting coded or identified use for a
particular study, with further contact
regarding new findings or to update an
informed consent.
 Permitting coded or identified use for any
study relating to the condition, with further
contact permitted regarding new discoveries
orupdates for informedconsent for futureuse.
 For all HBM samples a set an expiration date, and
after which the samples and any and all PHI will
be destroyed along with HBM.
○ Verification of sample destruction will be sent
to individual subjects.
○ Or a generic notification to all study subjects.
Furthermore, the standards used for traditional
research should not necessarily be used for Omics
research. With a provocative title (“Ethics review
roulette”),31 Glasziou and Chalmers concluded that
ethical standards are essential for all types of evaluations,
yet the concept of “one size of ethics review fits all types
of evaluation” should be rejected. There is consensus
that standards inOmics and biobanking ethics need to be
optimized, and that multiple new approaches are devel-
oped to achieve such optimization.16,32–34
Another important issue is the huge differences
between the applications of the general ethical recom-
mendations for different IRBs. Several investigators
have described the differences regarding ethical require-
ments and submission particulars in European
nations.35,36 In an interesting investigation, Stamer and
colleagues37 compared ethical procedures in a multi-
center postoperative pain study. These investigators
observed that the approval process can range from less
than 2 weeks to more than 2 months, with participation
fees varying from 300 to 575 Euros. Additionally,
regarding informed consent, there were substantial
differences between centers not only regarding informa-
tion sheets of variable length (ranging from half a page
up to 2 pages) but also the nature of what constituted
informed consent. Written informed consent was
mandatory at 12 centers, only oral consent was required
at 10, with 1 center requiring no consent whatsoever.
The need for multiple ethical approvals for multicenter
studies and increasing ethical regulations and guidelines
have become barriers to research,38 especially in genetic/
Omic pain research (in which the ethical implications
associated with trial approval are even more signifi-
cant).35 In Europe, several ongoing projects are aimed at
centralizing IRB approval. Examples of these projects
include the European Clinical Research Infrastructures
Network (ECRIN; http://www.ecrin.org/) and the Euro-
pean Forum for Good Clinical Practice (EFGCP; http://
www.efgcp.be/EFGCPRReports.asp). Although the
focus remains predominately on interventional trials,
there remains a need to adopt procedures more specific
to this type of research.
THE AMERICAN DILEMMAS AROUND INFORMED
CONSENT AND PRIVACY
In the United States, the situation is similar. However,
although privacy issues around pain pharmacogenomics
are relatively straightforward in nations with National
Health Services, in the United States, where a national
healthcare system does not exist, it takes a very
conservative approach when it comes to privacy
issues,39 which results in certain unique ethical
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quandaries associated with privacy. Among the most
distressing of these issues is the limitation of the Genetic
Information Nondiscrimination Act (GINA) of 2008.
GINA was heralded as “the first civil rights legislation of
the new millennium”40 and was met with considerable
enthusiasm until the weaknesses of the legislation were
better understood.41 To its credit, GINA prohibits
health insurers from denying coverage to an individual
for having heightened genetic risk for developing a
disease—provided that the individual is asymptomatic.42
Unfortunately, the law does not prohibit insurers from
denying coveragewhen applying for disability, long-term
care, or life insurance.43 While Rothstein44 has argued
that GINA has symbolic value in alleviating fears of
discrimination and thereby allows individuals at risk to
use genetic testing more freely, a recent study45 deter-
mined that the weaknesses of the law in regard to
providing privacy of results remains a concern for the
majority of thosewhowould consider such testing.Given
the severity of the discrimination already experienced by
those suffering from chronic pain,46 the American
government has not yet enacted legislation that ade-
quately protects the privacy of pharmacogenomic testing
for pain—resulting in tragic limitations of its empirical
investigation and clinical utility.
ADDITIONAL CONCERNS
Omics research in patients with pain is a new and
innovative field that has the potential to produce a wide
array of novel medical treatments. The potential uses of
this innovative research include identifying biomarkers
for specific clinical pathologies (eg, low back pain),
understanding the variation of gene expression in cytoki-
nes genes and opioid pathways in several clinical models
of acute pain, and identifying single nucleotide polymor-
phisms (SNPs) related to individual variability of pain
experience. These issues add new ethical complexity to
the scenario.47,48 The misuse of Omics data in research
indeed involves potential risks, but its inclusion in clinical
practice opens the door to other risks as well. What
would happen, for example, if employerswere to use pain
sensitivity information to exclude employees with a high
risk for back pain? Or if an insurance company were to
use them to avoid covering high-risk individuals? These
possibilities are not necessarily as remote as one may
believe, particularly given their histories in the United
States. In 2001, the Burlington Northern Santa Fe
Railway Company was sued by the Equal Employment
Opportunity Commission, which alleged that the
company discriminated against its own employees when
it performed genetic testing of their employees using
blood samples obtained without individual informed
consent specific for the genetic testing and without the
employee’s knowledge.49 Nonetheless, insurers’ misuse
and potential abuse of information arising from Omics
studies of pain is one of many hypothetical and practical
ethical dilemmaspotentially associatedwith any research
studies that collect and generate genetic data.
An additional topic of ongoing concern is protection
of vulnerable populations. When designing a pain
research study, one must ensure that subjects are able
to correctly comprehend the scope of the clinical trial, to
“correctly” express pain, and to provide legitimate
consent.50 Particularly at the cognitive level, the ability
to comprehend and provide consent becomes even more
critical as an increasing number of pain research projects
begin to utilize HBMs, specifically when subjects are
asked to understand complex implications and potential
misuse of information as a result of participating in a
research study with HBMs. Furthermore, at a physio-
logical level, one must be careful to prevent unnecessary
pain in research subjects, either deliberately or uninten-
tionally by design for the sake of clinical pain research.
A particularly salient example pertains to cases of fetal,
neonatal, and infant pain. In a famous case performed in
1985, open heart surgery was performed on a premature
infant named Jeffrey Lawson while the infant was fully
awake and conscious during the entire operation with-
out any analgesic or anesthetic administered to the
infant either perioperatively or intra-operatively. The
anesthesiologist at the time argued that it had not ever
been established that pain was experienced in premature
babies.51 In considering a recent study proposal, how-
ever, an IRB rejected a research protocol using placebo
to study neonatal pain in an intensive care setting.52
Despite such precedents in the research arena, invasive
and potentially painful fetal procedures continue to be
performed in clinical practice. Another important area
of research is pain in elderly patients, due to the high
prevalence of both pain and cognitive impairments in
the elderly population. It is a well-documented fact that
difficulties associated with the assessment of pain in
elderly and/or cognitively impaired subjects lead to a
suboptimal management of pain.53,54 There are several
methodological obstacles in research in this field54; for
example, in the contemporary practice of clinical
studies, cognitively impaired patients are excluded from
research protocols. The improvement of pain monitor-
ing in patients could be a new way to improve our
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knowledge in these areas. The principal aim would be to
obtain the minimum intensity of pain essential to
complete the objectives of the research.47
CONCLUSIONS
Although informed consent is widely accepted in many
countries, this understanding varies according to the
culture and background of the different healthcare
personnel involved. Informed consent in Pain-Omics
research involves more than a few particular ethical
concerns, including those associated with the biobank-
ing of HBMs and the future use of stored material for
further indeterminate research. Careful efforts to clarify
practice and the critical role of informed consent are
necessary to bridge the gap between the current realities
of informed consent and those of the desired future
direction.55 Continued persistent and thoughtful efforts
to bring the theoretical and practical realities of
informed consent closer together are essential. The
European scientific community would benefit from
developing a protocol aiming to protect human subjects
from harm and exploitation and to reduce the bureau-
cratic burden of procedures for managing the enormous
quantity of information involved in Pain-Omics. The
potential future benefits to the practice of medicine and
society as a whole associated with such an innovative
type of approach are simply dramatic.
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